[go: up one dir, main page]

ATE325795T1 - Rho-kinase inhibitoren - Google Patents

Rho-kinase inhibitoren

Info

Publication number
ATE325795T1
ATE325795T1 AT02719303T AT02719303T ATE325795T1 AT E325795 T1 ATE325795 T1 AT E325795T1 AT 02719303 T AT02719303 T AT 02719303T AT 02719303 T AT02719303 T AT 02719303T AT E325795 T1 ATE325795 T1 AT E325795T1
Authority
AT
Austria
Prior art keywords
kinase inhibitors
rho kinase
rho
inhibitors
kinase
Prior art date
Application number
AT02719303T
Other languages
English (en)
Inventor
Dhanapalan Nagarathnam
Davoud Asgari
Jianxing Shao
Xiao-Gao Liu
Uday Khire
Chunguang Wang
Barry Hart
Stephen Boyer
Olaf Weber
Mark Lynch
Donald Bankston
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE325795T1 publication Critical patent/ATE325795T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02719303T 2001-03-23 2002-03-22 Rho-kinase inhibitoren ATE325795T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27797401P 2001-03-23 2001-03-23
US31534101P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
ATE325795T1 true ATE325795T1 (de) 2006-06-15

Family

ID=26958819

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02719303T ATE325795T1 (de) 2001-03-23 2002-03-22 Rho-kinase inhibitoren

Country Status (19)

Country Link
US (3) US20030125344A1 (de)
EP (1) EP1370553B1 (de)
JP (1) JP4329003B2 (de)
AR (1) AR035791A1 (de)
AT (1) ATE325795T1 (de)
AU (1) AU2002250394A1 (de)
CA (1) CA2441492C (de)
CY (1) CY1107475T1 (de)
DE (1) DE60211317T2 (de)
DK (1) DK1370553T3 (de)
ES (1) ES2264477T3 (de)
HN (1) HN2002000067A (de)
MX (1) MXPA03008658A (de)
MY (1) MY134783A (de)
PE (1) PE20021011A1 (de)
PT (1) PT1370553E (de)
TW (1) TWI261055B (de)
UY (1) UY27224A1 (de)
WO (1) WO2002076976A2 (de)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020958A1 (es) * 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
AU2002250394A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
WO2002100833A1 (en) * 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2496797C (en) 2002-08-29 2012-01-10 Santen Pharmaceutical Co., Ltd. Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin
CA2520465A1 (en) 2003-03-28 2004-10-14 Scios Inc. Bi-cyclic pyrimidine inhibitors of tgf.beta.
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
EP1610774A4 (de) * 2003-04-09 2008-07-16 Exelixis Inc Tie-2 modulatoren und anwendungsverfahren
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
US20080146562A1 (en) * 2003-08-08 2008-06-19 Ulysses Pharmaceutical Products Inc., Halogenated quinazolinyl nitrofurans as antibacterial agents
BRPI0413372A (pt) * 2003-08-08 2006-10-17 Ulysses Pharmaceutical Product composto e composições de nitrofuranos de quinazolinil halogenados, seus métodos de preparação e usos como agentes antibacterianos
HRP20080329T3 (en) 2003-09-16 2008-08-31 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US20070123561A1 (en) * 2003-10-06 2007-05-31 Dennis Lee Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
EP1670466A4 (de) * 2003-10-06 2007-04-25 Glaxo Group Ltd Zubereitung von 1,6,7-trisubstituierten azabenzimidazolen als kinasehemmer
ATE552834T1 (de) * 2003-10-06 2012-04-15 Glaxosmithkline Llc Zubereitung von 1,6-disubstituierten azabenzimidazolen als kinasehemmer
CN1863779B (zh) 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
CA2553423C (en) 2004-01-23 2012-03-20 Amgen Inc. Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
EP1711495A2 (de) 2004-01-23 2006-10-18 Amgen Inc. Chinolin-, chinazolin-, pyridin- und pyrimidinverbindungen und deren verwendung bei der behandlung von entzündungen, angiogenese und krebs
US7632840B2 (en) 2004-02-03 2009-12-15 Astrazeneca Ab Quinazoline compounds for the treatment of hyperproliferative disorders
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
JP4991527B2 (ja) * 2004-06-01 2012-08-01 ユニバーシティ オブ バージニア パテント ファンデーション 二つの部分からなる低分子量の癌および血管新生の抑制剤
EP1781293A1 (de) 2004-06-04 2007-05-09 Amphora Discovery Corporation Verbindungen auf chinolin- und isochinolin-basis mit atp-verwendender enzymhemmender aktivität und zusammensetzungen und verwendungen daraus
JP2007269629A (ja) * 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
BRPI0516751A (pt) 2004-09-30 2008-09-16 Tibotec Pharm Ltd pirimidinas bicìclicas que inibem hcv
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
EP1833832A1 (de) * 2004-12-31 2007-09-19 GPC Biotech AG Naphthyridinverbindungen als rock-inhibitoren
JP2006219395A (ja) * 2005-02-09 2006-08-24 Koei Chem Co Ltd ビピリジン化合物の製造方法
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US8252806B2 (en) 2005-03-14 2012-08-28 Neurosearch A/S Potassium channel modulating agents and their medical use
KR20070122194A (ko) 2005-03-25 2007-12-28 티보텍 파마슈티칼즈 리미티드 Ｈｃｖ의 헤테로비사이클릭 저해제
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
PT1899322E (pt) 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
JP5220414B2 (ja) 2005-08-30 2013-06-26 旭化成ファーマ株式会社 スルホンアミド化合物
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
WO2007142323A1 (ja) 2006-06-08 2007-12-13 Ube Industries, Ltd. 側鎖にスピロ環構造を有する新規インダゾール誘導体
WO2007146230A2 (en) * 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
MX2009006081A (es) * 2006-12-08 2009-06-17 Irmc Llc Compuestos y composiciones como inhibidores de cinasa de proteina.
GEP20125691B (en) 2006-12-08 2012-11-26 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008079945A2 (en) * 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
US7998949B2 (en) 2007-02-06 2011-08-16 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
WO2008105442A1 (ja) 2007-02-28 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド誘導体
CA2690753C (en) 2007-07-02 2013-08-13 Asahi Kasei Pharma Corporation Sulfonamide compound and crystal thereof
KR20210070407A (ko) 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
CA2723989C (en) 2008-05-13 2017-04-25 Astrazeneca Ab Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN101463014B (zh) * 2008-12-26 2013-07-10 复旦大学 二芳基苯并嘧啶类衍生物及其药物组合物和用途
AU2010222848A1 (en) * 2009-03-09 2011-10-20 Surface Logix, Inc. Rho kinase inhibitors
DK2421957T3 (da) 2009-04-22 2021-01-25 Viacyte Inc Cellesammensætninger afledt af dedifferentierede omprogrammerede celler
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
RU2012117719A (ru) 2009-10-16 2013-11-27 Зе Скрипс Ресеч Инститьют Индукция плюрипотентных клеток
EP4364797A3 (de) 2009-10-19 2024-07-10 FUJIFILM Cellular Dynamics, Inc. Herstellung von kardiomyozyten
CN102753179A (zh) 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2528606B1 (de) 2010-01-28 2014-09-24 Alexander Levitzki Auf chinazolin basierende t-zell-proliferationshemmer
EP2566477B1 (de) * 2010-05-07 2015-09-02 GlaxoSmithKline Intellectual Property Development Limited Aminochinoline als kinasehemmer
WO2011159684A2 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
CA2813704A1 (en) 2010-10-05 2012-04-12 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
KR20140063501A (ko) 2010-12-22 2014-05-27 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
CA2831609C (en) 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
EP2732029B1 (de) 2011-07-11 2019-01-16 FUJIFILM Cellular Dynamics, Inc. Verfahren zur zellprogrammierung und genommanipulation
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
SI2788472T1 (sl) 2011-12-06 2019-04-30 Astellas Institute For Regenerative Medicine Način usmerjene diferencijacije, produciranja endotelijskih celic roženice
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
EP2628482A1 (de) 2012-02-17 2013-08-21 Academisch Medisch Centrum Rho Kinase Inhibitoren in der Verwendung zur Behandlung von Neuroblastoma
US9764063B2 (en) 2012-03-15 2017-09-19 Iheart Japan Corporation Method for producing mixed cell population of cardiomyocytes and vascular cells from induced pluripotent stem cell
US9334475B2 (en) 2012-04-06 2016-05-10 Kyoto University Method for inducing erythropoietin-producing cell
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
AR094707A1 (es) 2013-02-21 2015-08-19 Glaxosmithkline Ip Dev Ltd Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10266807B2 (en) 2013-04-03 2019-04-23 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
ES2794074T3 (es) 2013-06-11 2020-11-17 Univ Kyoto Método para producir células precursoras renales
ES2806135T3 (es) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd Nuevos inhibidores de bromodominios bicíclicos
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
JP6548576B2 (ja) 2013-07-30 2019-07-24 京都府公立大学法人 角膜内皮細胞マーカー
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
EP3031905A4 (de) 2013-08-07 2017-04-26 Kyoto University Verfahren zur herstellung bauchspeicheldrüsenhormon-produzierender zellen
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
CN104903312B (zh) * 2013-10-07 2019-01-29 卡德门企业有限公司 Rho激酶抑制剂
MX383328B (es) 2013-10-31 2025-03-13 Kyoto Prefectural Public Univ Corp Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3074508B1 (de) 2013-11-27 2019-11-06 Kyoto Prefectural Public University Corporation Verwendung von laminin zur hornhautendothel-zellkultur
WO2015112739A1 (en) * 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
EP3805369B1 (de) 2014-03-04 2025-09-03 Fate Therapeutics, Inc. Verbesserte neuprogrammierungsverfahren und zellkulturplattformen
EP3119881B1 (de) 2014-03-21 2023-03-01 FUJIFILM Cellular Dynamics, Inc. Herstellung von von dopaminergischen neuronen aus dem mittelhirn
JP6730608B2 (ja) 2014-05-21 2020-07-29 国立大学法人京都大学 膵芽細胞の製造方法および膵芽細胞を含む膵疾患治療剤
CN107075469A (zh) 2014-06-27 2017-08-18 加利福尼亚大学董事会 培养的哺乳动物角膜缘干细胞、其产生方法和其用途
CN105367555B (zh) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
WO2016104717A1 (ja) 2014-12-26 2016-06-30 国立大学法人京都大学 肝細胞誘導方法
EP3283479B1 (de) * 2015-04-01 2022-12-14 Rigel Pharmaceuticals, Inc. Tgf-beta inhibitoren
EP4088719A1 (de) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur behandlung von kapillarer nichtperfusion der netzhaut
US12048761B2 (en) 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
CN108291237B (zh) 2015-10-16 2023-11-21 菲特治疗公司 用于诱导和维护基态多能性的平台
JP6983771B2 (ja) 2015-10-30 2021-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
PL3416658T3 (pl) 2016-02-15 2023-09-04 Kyoto Prefectural Public University Corporation Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
EP3500664B1 (de) 2016-08-16 2021-09-22 FUJIFILM Cellular Dynamics, Inc. Verfahren zur differenzierung pluripotenter zellen
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN106518790B (zh) * 2016-11-02 2019-01-15 河南省商业科学研究所有限责任公司 一种2,4-二氯喹唑啉的合成方法
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN110291073A (zh) 2016-12-13 2019-09-27 贝塔医疗私人有限公司 乙酰肝素酶抑制剂及其用途
KR102594102B1 (ko) 2017-05-25 2023-10-25 고쿠리츠 다이가쿠 호진 교토 다이가쿠 중간 중배엽 세포로부터 신장 전구 세포로의 분화 유도 방법 및 다능성 줄기세포로부터 신장 전구 세포로의 분화 유도 방법
KR102469161B1 (ko) 2017-06-30 2022-11-23 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
AU2018294054B2 (en) * 2017-06-30 2022-05-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019045824A1 (en) * 2017-09-01 2019-03-07 Kadmon Corporation, Llc ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO
US20210363483A1 (en) 2017-11-10 2021-11-25 Regenesis Science Co., Ltd. Method for producing cultured cell, and method for producing therapeutic agent for spinal cord injury disease
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CA3086457A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
US20210062139A1 (en) 2017-12-28 2021-03-04 Kaneka Corporation Cell aggregation suppressor
JP7349911B2 (ja) 2017-12-28 2023-09-25 株式会社カネカ 細胞凝集促進剤
JP7336386B2 (ja) 2017-12-28 2023-08-31 株式会社カネカ 多能性幹細胞凝集抑制剤
WO2019160148A1 (ja) 2018-02-19 2019-08-22 大日本住友製薬株式会社 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
US20210332329A1 (en) 2018-07-23 2021-10-28 Kyoto University Novel renal progenitor cell marker and method for concentrating renal progenitor cells using same
US12281308B2 (en) 2018-08-29 2025-04-22 University Of Massachusetts Inhibition of protein kinases to treat Friedreich ataxia
US20210207088A1 (en) 2018-08-31 2021-07-08 The Doshisha Composition and method for preserving or culturing ocular cells
AU2019352309A1 (en) 2018-10-02 2021-03-11 The Doshisha Method and vessel for preserving corneal endothelial cells
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
US12435311B2 (en) 2018-12-21 2025-10-07 The University Of Osaka Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
US20220169977A1 (en) 2019-03-29 2022-06-02 Kaneka Corporation Cell population including pluripotent stem cells and production method thereof
WO2020230832A1 (ja) 2019-05-15 2020-11-19 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
JP7807073B2 (ja) 2020-02-27 2026-01-27 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用
WO2021220132A1 (en) 2020-04-27 2021-11-04 Novartis Ag Methods and compositions for ocular cell therapy
JP7798294B2 (ja) 2021-01-08 2026-01-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法
US20240219375A1 (en) 2021-04-07 2024-07-04 FUJIFILM Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
CN117242173A (zh) 2021-05-03 2023-12-15 安斯泰来再生医药协会 产生成熟角膜内皮细胞的方法
WO2022259721A1 (ja) 2021-06-10 2022-12-15 味の素株式会社 間葉系幹細胞の製造方法
EP4386083A4 (de) 2021-08-11 2025-11-12 Univ Kyoto Verfahren zur herstellung interstitieller nierenvorläuferzellen, erythropoietinproduzierende zellen und verfahren zur herstellung reninproduzierender zellen
US20230078230A1 (en) 2021-09-13 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
KR20240110954A (ko) 2021-11-11 2024-07-16 학교법인 도시샤 각막 내피 세포의 냉동보존 제제 및 상기 냉동보존 제제를 생산하기 위한 방법
KR20240103018A (ko) 2021-11-19 2024-07-03 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 시트상 망막 조직의 제조 방법
WO2023153464A1 (ja) 2022-02-09 2023-08-17 住友ファーマ株式会社 多能性幹細胞から中脳底板領域の神経系細胞への分化における、培養液中の細胞の分化能を判定する方法
IL319123A (en) 2022-08-31 2025-04-01 Univ Kyoto Method for producing naïve pluripotent stem cells
WO2024070494A1 (ja) 2022-09-26 2024-04-04 国立大学法人京都大学 膵内胚葉細胞の製造方法
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
KR20250159016A (ko) 2023-03-03 2025-11-07 고쿠리츠 다이가쿠 호진 교토 다이가쿠 프라임형 다능성 줄기 세포의 제조 방법
TW202444894A (zh) 2023-03-29 2024-11-16 日商住友製藥股份有限公司 視網膜組織之製造方法
WO2024242069A1 (ja) 2023-05-19 2024-11-28 国立大学法人京都大学 神経堤細胞の製造方法
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14679A (en) * 1856-04-15 Joel h
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US5245038A (en) * 1987-11-06 1993-09-14 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
DK0498722T3 (da) * 1991-02-07 1998-03-09 Roussel Uclaf Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5245036A (en) * 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ID19609A (id) * 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
ES2286834T5 (es) * 1996-08-12 2011-01-31 Mitsubishi Tanabe Pharma Corporation Medicamentos que comprenden un inhibidor de la rho quinasa.
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
IL141434A0 (en) * 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU2096100A (en) * 1998-12-23 2000-07-31 Bayer Aktiengesellschaft Polycarbonates with a low yellowness index
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
SK288365B6 (sk) * 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002059111A2 (en) * 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002250394A1 (en) * 2001-03-23 2002-10-08 Bayer Corporation Rho-kinase inhibitors
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
ATE423104T1 (de) * 2001-11-03 2009-03-15 Astrazeneca Ab Quinazolin derivate als antitumor-mittel
GB0128108D0 (en) * 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CA2472619A1 (en) * 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
DE60318177T2 (de) * 2002-01-23 2008-10-09 Bayer Pharmaceuticals Corp., West Haven Rho-kinase inhibitoren
KR101093345B1 (ko) * 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
EP1928861B1 (de) * 2005-09-20 2010-11-17 AstraZeneca AB 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs

Also Published As

Publication number Publication date
WO2002076976A3 (en) 2002-12-12
AU2002250394A1 (en) 2002-10-08
MY134783A (en) 2007-12-31
DK1370553T3 (da) 2006-09-11
EP1370553B1 (de) 2006-05-10
JP4329003B2 (ja) 2009-09-09
CA2441492A1 (en) 2002-10-03
US20100137324A1 (en) 2010-06-03
US20060142313A1 (en) 2006-06-29
ES2264477T3 (es) 2007-01-01
CY1107475T1 (el) 2013-03-13
UY27224A1 (es) 2002-10-31
DE60211317T2 (de) 2007-04-12
JP2004524350A (ja) 2004-08-12
AR035791A1 (es) 2004-07-14
MXPA03008658A (es) 2005-04-11
HN2002000067A (es) 2003-10-24
PT1370553E (pt) 2006-09-29
WO2002076976A2 (en) 2002-10-03
TWI261055B (en) 2006-09-01
EP1370553A2 (de) 2003-12-17
PE20021011A1 (es) 2003-02-01
CA2441492C (en) 2011-08-09
US20030125344A1 (en) 2003-07-03
DE60211317D1 (de) 2006-06-14
HK1061030A1 (en) 2004-09-03

Similar Documents

Publication Publication Date Title
ATE325795T1 (de) Rho-kinase inhibitoren
ATE353889T1 (de) Rho-kinase inhibitoren
ATE505471T1 (de) Azaindol-kinaseinhibitoren
IS6968A (is) Nýir týrósínkínasa tálmar
DE60234125D1 (de) E inhibitoren
DE60320933D1 (de) Rho-kinase inhibitoren
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
IS7599A (is) Heterósýklískir kínasatálmar
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
NO20021820L (no) Tyrosinkinaseinhibitorer
DK1650203T3 (da) Quinolinonderivater som tyrosinkinaseinhibitorer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
EP1161433A4 (de) Tyrosin-kinase-inhibitoren
DE60129794D1 (de) Pyrrol substituierte indolin-2-on protein kinase inhibitoren
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
ATE524441T1 (de) Vla-4-inhibitoren
ATE484496T1 (de) Metalloproteinaseinhibitoren
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
BR0207810A (pt) inibidores de deformilase de peptìdeo
NO20032807L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
EP1570847A4 (de) Phosphodiesterase 10a-hemmer
EP1670422A4 (de) Identifizierung von kinase-inhibitoren
EP1651209A4 (de) Tyrosin-kinase-hemmer
AR028075A1 (es) Inhibidores de la peptido-desformilasa

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1370553

Country of ref document: EP